Zylox-Tonbridge Reports 2025 Annual Results with Revenue Exceeding RMB 1.06 Billion and Net Profit Up 143.7% Year-over-Year

About this update from Zylox-tonbridge Medical Technology Co., Ltd. Class H

[{"type":"text","content":"HANGZHOU, China, March 17, 2026 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company") today announced its annual results for the year ended December 31, 2025.","length":234,"tagName":"p"},{"type":"text","content":"In 2025, the Company delivered another year of strong growth and materially improved profitability. Revenue rose 35.1% year-over-year to RMB 1.06 billion, while net profit increased 143.7% year-over-year to RMB 244 million. Growth was driven by continued commercial momentum across core products, rapid growth in international business, and further improvement in operating efficiency.","length":385,"tagName":"p"},{"type":"text","content":"The Company's neurovascular intervention business generated revenue of RMB 676 million, up 28.0% year-over-year, while revenue from peripheral vascular intervention increased 50.3% year-over-year to RMB 379 million. Revenue from markets outside Mainland China reached RMB 48.65 million, up 115.5% year-over-year, reflecting continued progress in international market access and channel expansion.","length":400,"tagName":"p"},{"type":"text","content":"Despite the continued impact of volume-based procurement in China, Zylox-Tonbridge maintained a gross margin of 72.1% in 2025 and reported non-IFRS adjusted net profit of RMB 273 million, reflecting improving operating leverage as the business scaled. As of the end of the reporting period, total available financial resources, including cash and cash equivalents, term deposits and financial assets measured at fair value through profit or loss, amounted to RMB 2.60 billion.","length":476,"tagName":"p"},{"type":"text","content":"Supported by its solid operating performance and strong liquidity position, the Company proposed a final dividend of RMB 0.22 per share (tax inclusive) for 2025, representing a payout ratio of approximately 30%. In 2025, the Company repurchased shares with an aggregate value of more than HK$130 million, and going forward, it intends to further increase the scale of share repurchases to enhance shareholder returns.","length":417,"tagName":"p"},{"type":"text","content":"Zylox-Tonbridge continued to strengthen its long-term growth foundation through ongoing commercialization and innovation. Its sales network now covers more than 3,300 hospitals i...

More updates from Zylox-tonbridge Medical Technology Co., Ltd. Class H